Cas9 (S. pyogenes) (7A9-3A3) Mouse Monoclonal Antibody (SignalFlexTMAlexa Fluor®350 Conjugate)#45564,Cell Signaling Technology (CST),45564

Cas9 (S. pyogenes) (7A9-3A3) Mouse Monoclonal Antibody (SignalFlexTM Alexa Fluor®350 Conjugate) recognizes transfected levels of total Cas9 protein. This antibody does not cross-react with Cas9 ( S. aureus), FnCpf1, and AsCpf1 proteins.

Host

Mouse

Reactivity

All Species Expected

Conjugate

SignalFlexTMAlexa Fluor®350 Conjugate

Platform ID

BAB316837254

Cell Signaling Technology (CST)

Headquarters

3 Trask Lane Danvers, MA 01923

Contact

Tel: 877-616-2355,978-867-2388
Fax: 877-616-2355

Product Specifications
Scientific Background
Synonyms

Specifications

NameCas9 (S. pyogenes) (7A9-3A3) Mouse Monoclonal Antibody (SignalFlexTMAlexa Fluor®350 Conjugate)#45564
Cat. No.45564
Accession NumberQ99ZW2, 901176
Gene ID (Entrez)901176
HostMouse
SensitivityTransfected Only
ReactivityAll Species Expected
ConjugationSignalFlexTMAlexa Fluor®350 Conjugate
ImmunogenIgG1
FormulationSignalFlexTM conjugates are produced using highly validated Cell Signaling Technology®primary antibodies and conjugation methods that have been rigorously tested, ensuring high-quality conjugates and lot-to-lot consistency. These conjugates are quality control tested by size exclusion chromatography (SEC) to determine antibody integrity. However, they are not tested on specific assays.Optimal dilutions/concentrations should be determined by the end user. When performing flow cytometry, we recommend using an isotype control conjugate at the same concentration as the antibody conjugate.
StorageSupplied in PBS (pH 7.2), less than 0.1% sodium azide, and 2 mg/mL BSA. Store at 4°C.Do not aliquot the antibody. Protect from light. Do not freeze.
Regulatory StatusResearch Use Only

Scientific Background

The CRISPR associated protein 9 (Cas9) is an RNA-guided DNA nuclease and part of theStreptococcus pyogenesCRISPR antiviral immunity system that provides adaptive immunity against extrachromosomal genetic material (1). The CRISPR antiviral mechanism of action involves three steps: (i), acquisition of foreign DNA by host bacterium; (ii), synthesis and maturation of CRISPR RNA (crRNA) followed by the formation of RNA-Cas nuclease protein complexes; and (iii), target interference through recognition of foreign DNA by the complex and its cleavage by Cas nuclease activity (2). The type II CRISPR/Cas antiviral immunity system provides a powerful tool for precise genome editing and has potential for specific gene regulation and therapeutic applications (3). The Cas9 protein and a guide RNA consisting of a fusion between a crRNA and a trans-activating crRNA (tracrRNA) must be introduced or expressed in a cell. A 20-nucleotide sequence at the 5' end of the guide RNA directs Cas9 to a specific DNA target site. As a result, Cas9 can be "programmed" to cut various DNA sites bothin vitroand in cells and organisms. CRISPR/Cas9 genome editing tools have been used in many organisms, including mouse and human cells (4,5). Research studies demonstrate that CRISPR can be used to generate mutant alleles or reporter genes in rodents and primate embryonic stem cells (6-8).Horvath, P. and Barrangou, R. (2010)Science327, 167-70.Wiedenheft, B. et al. (2012)Nature482, 331-8.Singh, P. et al. (2015)Genetics199, 1-15.Cong, L. et al. (2013)Science339, 819-23.Mali, P. et al. (2013)Science339, 823-6.Li, D. et al. (2013)Nat Biotechnol31, 681-3.Shen, B. et al. (2013)Cell Res23, 720-3.Niu, Y. et al. (2014)Cell156, 836-43.Alternate Namescas9; CRISPR-associated endonuclease Cas9/Csn1; csn1

Synonyms

cas9; CRISPR-associated endonuclease Cas9/Csn1; csn1

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.